Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31586624 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2KDM4EASPH | |
| SCHEMBL20917216 | 0.82 | DGAT1 (0.40) | ATRMEN1KMT2A | |
| SCHEMBL1855234 | 0.82 | PTGS2 (0.33) | EPRS1MEN1KMT2AL3MBTL1 | |
| SCHEMBL30409470 | 0.82 | PTGS2 (0.33) | EPRS1MEN1KMT2AL3MBTL1 | |
| SCHEMBL30139591 | 0.82 | DGAT1 (0.40) | ATRMEN1KMT2A | |
| SCHEMBL20913083 | 0.80 | HDAC6 (0.37) | ATRALOX15MEN1KMT2A | |
| SCHEMBL24149183 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2ALOX15TDP1 | |
| SCHEMBL15109545 | 0.79 | — | — | |
| SCHEMBL595464 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTSMN1; SMN2KDM4EATR | |
| SCHEMBL3792291 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTSMN1; SMN2KDM4EASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024175925-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-114671878-B | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022135534-A1 | SUBSTITUTED NITROGEN-CONTAINING BICYCLIC COMPOUND AND USE THEREOF | 广东东阳光药业有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114671878-A | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3085696-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | ALDH1A1 3610/4885MAPT 4391/4885SMN1; SMN2 4746/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | ALDH1A1 3377/4885MAPT 4342/4885SMN1; SMN2 4727/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ALDH1A1 2467/4885MAPT 3029/4885SMN1; SMN2 1790/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | ALDH1A1 2467/4885MAPT 3029/4885SMN1; SMN2 1790/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ALDH1A1 2176/4885MAPT 4106/4885SMN1; SMN2 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.